281 related articles for article (PubMed ID: 2503176)
1. Inhibin: a new circulating marker of hydatidiform mole?
Yohkaichiya T; Fukaya T; Hoshiai H; Yajima A; de Kretser DM
BMJ; 1989 Jun; 298(6689):1684-6. PubMed ID: 2503176
[TBL] [Abstract][Full Text] [Related]
2. Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit.
Badonnel Y; Barbé F; Legagneur H; Poncelet E; Schweitzer M
Clin Endocrinol (Oxf); 1994 Aug; 41(2):155-62. PubMed ID: 7523000
[TBL] [Abstract][Full Text] [Related]
3. Circulating inhibin forms in patients with hydatidiform mole.
Kato T; Seki K; Matsui H; Sekiya S
Gynecol Obstet Invest; 2002; 54(2):114-7. PubMed ID: 12566755
[TBL] [Abstract][Full Text] [Related]
4. Serum activin A and inhibin A. New clinical markers for hydatidiform mole.
Florio P; Severi FM; Cobellis L; Danero S; Bomè A; Luisi S; Petraglia F
Cancer; 2002 May; 94(10):2618-22. PubMed ID: 12173329
[TBL] [Abstract][Full Text] [Related]
5. Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy?
Pautier P; Ghione S; Brailly-Tabard S; Lhommé C; Morice P; Bidart JM
Hum Reprod; 2001 Nov; 16(11):2434-7. PubMed ID: 11679534
[TBL] [Abstract][Full Text] [Related]
6. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of serum inhibin, 17 beta-estradiol and progesterone in cases of hydatidiform mole.
Hegab HM; Schindler AE
Gynecol Endocrinol; 2004 Feb; 18(2):107-13. PubMed ID: 15195503
[TBL] [Abstract][Full Text] [Related]
8. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
9. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
10. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
11. Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
Chen RJ; Huang SC; Chow SN; Hsieh CY; Hsu HC
Br J Obstet Gynaecol; 1994 Apr; 101(4):330-4. PubMed ID: 8199080
[TBL] [Abstract][Full Text] [Related]
12. Serum relaxin in patients with hydatidiform mole.
Seki K; Uesato T; Tabei T; Kato K
Obstet Gynecol; 1986 Mar; 67(3):381-3. PubMed ID: 3945450
[TBL] [Abstract][Full Text] [Related]
13. Hydatidiform mole and post-evacuation regression patterns of serum beta human chorionic gonadotrophin.
Kamariah K; Satgunasingam N; Nasri NM; Ng KY
Med J Malaysia; 1993 Mar; 48(1):40-5. PubMed ID: 7688063
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of dimeric activin A are not a marker of placental tumors in the course of chemotherapy.
Florio P; Luisi S; Casarosa E; Genazzani AR; Pautier P; Lhommé C; Bidart JM; Driul PG; Petraglia F
J Endocrinol Invest; 1998 Mar; 21(3):166-9. PubMed ID: 9591212
[TBL] [Abstract][Full Text] [Related]
15. Natural history of hydatidiform mole after primary evacuation.
Lurain JR; Brewer JI; Torok EE; Halpern B
Am J Obstet Gynecol; 1983 Mar; 145(5):591-5. PubMed ID: 6829636
[TBL] [Abstract][Full Text] [Related]
16. Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease?
Earp KE; Hancock BW; Short D; Harvey RA; Fisher RA; Drew D; Sarwar N; Tidy JA; Winter MC; Chien P; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():117-119. PubMed ID: 30684876
[TBL] [Abstract][Full Text] [Related]
17. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
Elmer DB; Granai CO; Ball HG; Curry SL
Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
[TBL] [Abstract][Full Text] [Related]
18. The beta-subunit of chorionic gonadotrophin as a tumour marker in gestational trophoblastic disease.
Khoo SK; Daunter B
Aust N Z J Obstet Gynaecol; 1980 Feb; 20(1):35-42. PubMed ID: 6248013
[TBL] [Abstract][Full Text] [Related]
19. Second-trimester maternal serum markers in twin pregnancy with complete mole: report of 2 cases.
Lambert-Messerlian G; Pinar H; Rubin LP; De Paepe ME; Tantravahi U; Steinhoff MM; Russell M; Canick JA
Pediatr Dev Pathol; 2005; 8(2):230-4. PubMed ID: 15765203
[TBL] [Abstract][Full Text] [Related]
20. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
